Online Psychology Program for Chronic Pain After Surgery (ADOPT-TPS)

April 15, 2026 updated by: University Health Network, Toronto

Advancing Online Psychology Tools for the Transitional Pain Service (ADOPT-TPS): Pilot Feasibility and Efficacy Randomized-Controlled Trial of a Scalable, Online Psychology Intervention for Post-Surgical Pain and Opioid Use

This project will evaluate the feasibility of a new fully self-guided online Acceptance and Commitment Therapy (ACT) program entitled Advancing Online Psychology Tools for the Transitional Pain Service (ADOPT-TPS), developed on an online health application platform called Manage My Pain (MMP). The ACT program is designed to teach mindfulness skills and provide psychoeducation about post-surgical pain. The feasibility of the self-guided online program will be compared to a pre-existing psychologist-guided workshop that delivers the same program. It is anticipated that the self-guided online ACT program will be deemed feasible by participants.

Study Overview

Detailed Description

The Transitional Pain Service (TPS) at Toronto General Hospital is a multidisciplinary treatment program that aims to prevent chronic post-surgical pain (CPSP) and persistent opioid use after surgery. CPSP is a major public health concern impacting from 10% up to 70% of patients, depending on the type of surgery. Those experiencing CPSP are at higher risk for prolonged opioid use, which introduces challenges like addiction, misuse, and overdose. Acceptance and Commitment Therapy (ACT) is an evidence-based psychology intervention that is effective in reducing patients' risk of CPSP and opioid use. However, access to this intervention is currently limited to predominantly in-person, specialized hospital-based clinic settings like the TPS, which prioritize patients at highest risk for CPSP and often require physician referrals for quick access. There is a need for such treatment approaches to spread to other institutions and to be available for lower-risk post-surgery patients, yet the shortage of specialized pain psychologists creates a barrier to widespread dissemination. The current project will evaluate the feasibility of a novel fully self-guided online ACT intervention entitled Advancing Online Psychology Tools for the Transitional Pain Service (ADOPT-TPS), developed on a mobile health application platform called Manage My Pain (MMP). A randomized, controlled pilot feasibility trial will evaluate the efficacy of ADOPT-TPS by comparing it to a pre-existing psychologist-guided workshop. Once tested, this scalable, evidence-based online intervention can be easily implemented at institutions across Canada and beyond to address CPSP and opioid use without the need for specialized pain psychologists on staff.

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G 2N2
        • University Health Network- Toronto General Hospital
      • Toronto, Ontario, Canada, M5G 2N2
        • Toronto General Hospital- The Department of Anesthesia and Pain Management

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who received a post-surgical referral to the TPS
  • Patients who have access to a device that can connect to the Internet

Exclusion Criteria:

  • Patients who have received TPS psychology treatment
  • Patients with a known history of serious mental illness (e.g., psychosis and/or active mania)
  • Patients who have limited comprehension of English or comprehension deficits due to dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Self-guided Online ACT
The intervention is a self-guided ACT program delivered on an online platform. The program is developed based on the psychologist-guided ACT group intervention for chronic pain and opioid use after surgery.
Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.
Active Comparator: Psychologist-guided Online ACT
The psychologist-guided ACT group workshop is an evidence-based psychology intervention for chronic pain and opioid use after surgery.
Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
Other Names:
  • Psychologist-guided online ACT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of the online ACT program as assessed by the Feasibility Survey
Time Frame: Participants will be sent a link to fill out the measure within 1 week of completing their respective program.
A 10-item Likert scale (min possible score = 10, max possible score = 70). Higher scores indicate greater feasibility.
Participants will be sent a link to fill out the measure within 1 week of completing their respective program.
Acceptability of the online ACT program as assessed by the Treatment Evaluation Inventory - Short Form
Time Frame: Participants will be sent a link to fill out the measure within 1 week of completing their respective program.
A 9-item Likert scale (min possible score = 9, max possible score = 45). Higher scores indicate greater acceptability.
Participants will be sent a link to fill out the measure within 1 week of completing their respective program.
Retrospective Semi-structured Interview
Time Frame: Participants will be sent an invitation for an interview within 1 month after completing their respective program
A brief interview with a randomized subset of participants
Participants will be sent an invitation for an interview within 1 month after completing their respective program
Treatment Adherence as assessed by the Integration of ACT Skills Survey
Time Frame: Participants will be sent a link to complete the measure within 1 month after completing their respective program.
A 5-item Likert scale (min possible score = 5, max possible score = 35). Higher scores indicate greater treatment adherence
Participants will be sent a link to complete the measure within 1 month after completing their respective program.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Intensity as assessed by the Pain Numerical Rating Scale
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 4-item Likert scale (min possible score = 0, max possible score = 40). Higher scores indicate greater pain intensity.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Pain Interference as assessed by the PROMIS Pain Interference Scale - Short Form 8a
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 8-item Likert scale (min possible score = 8, max possible score = 40). Higher scores indicate greater pain interference.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Pain Medication Misuse as assessed by the PROMIS Prescription Pain Medication Misuse Scale - Short Form 7a
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 7-item Likert scale (min possible score = 7, max possible score = 5). Higher scores indicate greater pain medication misuse.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Pain Catastrophizing as assessed by the Pain Catastrophizing Scale
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 13-item Likert scale (min possible score = 0, max possible score = 52). Higher scores indicate greater pain catastrophizing.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Depressive symptoms as assessed by PROMIS Emotional Distress - Depression - Short Form 8b
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 8-item Likert scale (min possible score = 8, max possible score = 40). Higher scores indicate greater depressive symptoms.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Anxiety symptoms as assessed by the PROMIS Emotional Distress - Anxiety - Short Form 8A
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 8-item Likert scale (min possible score = 8, max possible score = 40). Higher scores indicate greater anxiety symptoms.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Psychological Inflexibility in Pain as measured by the Psychological Inflexibility in Pain Scale
Time Frame: Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
A 16-item Likert scale (min possible score = 16, max possible score = 112). Higher scores indicate greater psychological inflexibility in pain.
Participants will be sent a link to fill out the measure prior to starting their respective program, within 1 week of completing their respective program, and 1 month after completing their respective program.
Use of Study Platform as assessed by the Use of Manage My Pain Platform Survey
Time Frame: Participants will be sent a link to fill out the measure within 1 week of completing the respective program, and 1 month after completing their respective program.
A 5-item Likert scale (min possible score = 4, max possible score = 20). Higher scores indicate more frequent use of the platform.
Participants will be sent a link to fill out the measure within 1 week of completing the respective program, and 1 month after completing their respective program.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maxwell Slepian, PhD, C Psych, Toronto General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 20, 2024

Primary Completion (Actual)

March 31, 2026

Study Completion (Actual)

March 31, 2026

Study Registration Dates

First Submitted

December 27, 2023

First Submitted That Met QC Criteria

June 6, 2024

First Posted (Actual)

June 12, 2024

Study Record Updates

Last Update Posted (Actual)

April 17, 2026

Last Update Submitted That Met QC Criteria

April 15, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Relevant de-identified study data will be shared upon request.

IPD Sharing Time Frame

The data will become available after primary outcomes manuscript is published and will remain available for 10 years.

IPD Sharing Access Criteria

Request for access will be reviewed by the principle investigator and the study team and will be granted in accordance with University Health Network policies.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain, Acute

Clinical Trials on Self-Guided Online ACT Program

Subscribe